Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987973 | 1.00 | CNR1 (0.58) | CNR1KDM4ELMNATSHRALDH1A1 | |
| SCHEMBL6226020 | 0.85 | CNR1 (0.64) | CNR1ALDH1A1 | |
| SCHEMBL29988021 | 0.84 | CNR1 (0.57) | CNR1KDM4ELMNATSHRALDH1A1 | |
| SCHEMBL26409622 | 0.84 | CNR1 (0.57) | CNR1KDM4ELMNATSHRALDH1A1 | |
| SCHEMBL4481860 | 0.84 | CNR1 (0.62) | CNR1ALDH1A1 | |
| SCHEMBL29987992 | 0.81 | CNR1 (0.43) | CNR1KDM4ELMNATSHRALDH1A1 | |
| SCHEMBL26409579 | 0.81 | CNR1 (0.43) | CNR1KDM4ELMNATSHRALDH1A1 | |
| Lithium Ion SCHEMBL4481864 | 0.81 | CNR1 (0.60) | CNR1KDM4EALDH1A1HPGD | |
| SCHEMBL26409610 | 0.80 | CNR1 (0.43) | CNR1KDM4EALDH1A1PKMHPGD | |
| SCHEMBL29988638 | 0.77 | L3MBTL1 (0.46) | CNR1KDM4ELMNATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313980-B1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC (CA) | 2026-04-22 | — | — | EP | disclosed |
| EP-4685147-A2 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | Fedora Pharmaceuticals Inc. (CA) | 2026-01-28 | — | — | EP | disclosed |
| US-12528804-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | FEDORA PHARMACEUTICALS INC. (CA) | 2026-01-20 | — | — | US | disclosed |
| EP-4313980-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | Fedora Pharmaceuticals Inc. (CA) | 2024-02-07 | — | — | EP | disclosed |
| US-20230374005-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230374005-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230374005-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-11780832-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | FEDORA PHARMACEUTICALS INC. (CA) | 2023-10-10 | — | — | US | disclosed |
| US-11780832-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | FEDORA PHARMACEUTICALS INC. (CA) | 2023-10-10 | — | — | US | disclosed |
| US-11780832-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | FEDORA PHARMACEUTICALS INC. (CA) | 2023-10-10 | — | — | US | disclosed |
| US-20220324858-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC. (CA) | 2022-10-13 | — | — | US | disclosed |
| WO-2022208356-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | FEDORA PHARMACEUTICALS INC. (CA) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528804-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | LCT, LPO, CLSPN | CNR1 2778/4885KDM4E 4419/4885LMNA 1567/4885 |
| US-20230374005-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | LCT, VIP, LPO | CNR1 4802/4885KDM4E 4221/4885LMNA 665/4885 |
| US-11780832-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | LCT, VIP, LPO | CNR1 4797/4885KDM4E 4222/4885LMNA 662/4885 |
| US-20220324858-A1 | LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS | LCT, VIP, LPO | CNR1 4797/4885KDM4E 4222/4885LMNA 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.